NCT02252406View on ClinicalTrials.gov

Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

December 17, 2018

Study Completion Date

May 17, 2019

Conditions
Stable AnginaMetabolic Syndrome
Interventions
DRUG

Ranolazine

Ranolazine 500 mg from baseline to week 3 and 1000 mg thereafter until week 24

OTHER

Placebo

Matching placebo tablets daily for 24 weeks.

Trial Locations (1)

32209

University of Florida, Jacksonville

All Listed Sponsors
lead

University of Florida

OTHER

NCT02252406 - Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome | Biotech Hunter | Biotech Hunter